注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Jasper Therapeutics Inc 是一家专注于造血细胞移植疗法的生物技术公司。该公司已经开发了一些项目,如JSP191,一种正在进行临床开发的抗CD117的单克隆抗体,作为一种调节剂,清除接受造血细胞移植的患者骨髓中的造血干细胞。它旨在实现治疗性异体和自体造血细胞移植和基因疗法。该公司还提供一个临床前工程造血干细胞(eHSC)平台,旨在克服异体和自体基因编辑干细胞移植的局限性。该项目用于治疗和扩大造血干细胞疗法,以治愈威胁生命的癌症、地中海贫血症、镰状细胞疾病、遗传性疾病和自身免疫性疾病患者。JSP191在移植前清除骨髓中的造血干细胞。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Kurt von Emster | 55 | 2019 | Independent Director |
Christian W. Nolet | 65 | 2021 | Independent Director |
Ronald A. Martell | 61 | 2022 | President, CEO & Director |
Frederick R. Appelbaum | - | - | Member of Scientific Advisory Board |
Harry Malech | - | - | Member of Scientific Advisory Board |
Vishal Kapoor | 47 | 2023 | Independent Director |
Daniel C. Adelman | 66 | 2023 | Member of Scientific Advisory Board & Senior Clinical Advisor |
Anna Louise French | 35 | 2019 | Independent Director |
Arthur Weiss | - | - | Member of Scientific Advisory Board |
Jeffrey V. Ravetch | 72 | - | Member of Scientific Advisory Board |
Stephen J. Galli | 76 | 2023 | Member of Scientific Advisory Board |
Judith Anne Shizuru | 67 | 2018 | Co-Founder & Director |
Scott C. Brun | 55 | 2023 | Independent Director |
Thomas G. Wiggans | 72 | 2023 | Independent Chairman |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核